請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56071
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 黃德富(Tur-Fu Huang) | |
dc.contributor.author | Meng-Fang Chiang | en |
dc.contributor.author | 江孟芳 | zh_TW |
dc.date.accessioned | 2021-06-16T05:14:37Z | - |
dc.date.available | 2024-08-20 | |
dc.date.copyright | 2014-10-15 | |
dc.date.issued | 2014 | |
dc.date.submitted | 2014-08-18 | |
dc.identifier.citation | Ajizian SJ, English BK, Meals EA. 1999. Specific inhibitors of p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways block inducible nitric oxide synthase and tumor necrosis factor accumulation in murine macrophages stimulated with lipopolysaccharide and interferon-gamma. J Infect Dis 179(4):939-944.
Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29(7):1303-1310. Bone RC, Grodzin CJ, Balk RA. 1997. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 112(1):235-243. Borsch-Haubold AG, Pasquet S, Watson SP. 1998. Direct inhibition of cyclooxygenase-1 and -2 by the kinase inhibitors SB 203580 and PD 98059. SB 203580 also inhibits thromboxane synthase. J Biol Chem 273(44):28766-28772. Bradley JR. 2008. TNF-mediated inflammatory disease. J Pathol 214(2):149-160. Carter AB, Knudtson KL, Monick MM, Hunninghake GW. 1999. The p38 mitogen-activated protein kinase is required for NF-kappaB-dependent gene expression. The role of TATA-binding protein (TBP). J Biol Chem 274(43):30858-30863. Castellheim A, Brekke OL, Espevik T, Harboe M, Mollnes TE. 2009. Innate immune responses to danger signals in systemic inflammatory response syndrome and sepsis. Scand J Immunol 69(6):479-491. Cavaillon JM, Annane D. 2006. Compartmentalization of the inflammatory response in sepsis and SIRS. J Endotoxin Res 12(3):151-170. Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I, et al. 1999. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. J Pharmacol Exp Ther 290(2):551-560. Chen CC, Wang JK. 1999. p38 but not p44/42 mitogen-activated protein kinase is required for nitric oxide synthase induction mediated by lipopolysaccharide in RAW 264.7 macrophages. Mol Pharmacol 55(3):481-488. Chokri M, Freudenberg M, Galanos C, Poindron P, Bartholeyns J. 1989. Antitumoral effects of lipopolysaccharides, tumor necrosis factor, interferon and activated macrophages: synergism and tissue distribution. Anticancer Res 9(4):1185-1190. Cogswell JP, Godlevski MM, Wisely GB, Clay WC, Leesnitzer LM, Ways JP, Gray JG. 1994. NF-kappa B regulates IL-1 beta transcription through a consensus NF-kappa B binding site and a nonconsensus CRE-like site. J Immunol 153(2):712-723. Coussens LM, Werb Z. 2002. Inflammation and cancer. Nature 420(6917):860-867. Cuschieri J, Bulger E, Garcia I, Jelacic S, Maier RV. 2005. Calcium/calmodulin-dependent kinase II is required for platelet-activating factor priming. Shock 23(2):99-106. Delgado AV, McManus AT, Chambers JP. 2003. Production of tumor necrosis factor-alpha, interleukin 1-beta, interleukin 2, and interleukin 6 by rat leukocyte subpopulations after exposure to substance P. Neuropeptides 37(6):355-361. Dileepan KN, Page JC, Li Y, Stechschulte DJ. 1995. Direct activation of murine peritoneal macrophages for nitric oxide production and tumor cell killing by interferon-γ. Journal of Interferon & Cytokine Research 15(5):387-394. Dinarello CA. 2007. Historical insights into cytokines. Eur J Immunol 37 Suppl 1:S34-45. Fujihara M, Connolly N, Ito N, Suzuki T. 1994. Properties of protein kinase C isoforms (beta II, epsilon, and zeta) in a macrophage cell line (J774) and their roles in LPS-induced nitric oxide production. J Immunol 152(4):1898-1906. Gabay C. 2006. Interleukin-6 and chronic inflammation. Arthritis Res Ther 8 Suppl 2:S3. Gilroy DW, Lawrence T, Perretti M, Rossi AG. 2004. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3(5):401-416. Gray JG, Chandra G, Clay WC, Stinnett SW, Haneline SA, Lorenz JJ, Patel IR, Wisely GB, Furdon PJ, Taylor JD, et al. 1993. A CRE/ATF-like site in the upstream regulatory sequence of the human interleukin 1 beta gene is necessary for induction in U937 and THP-1 monocytic cell lines. Mol Cell Biol 13(11):6678-6689. Guzik TJ, Korbut R, Adamek-Guzik T. 2003. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 54(4):469-487. Han J, Lee JD, Bibbs L, Ulevitch RJ. 1994. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265(5173):808-811. Herrera-Velit P, Reiner NE. 1996. Bacterial lipopolysaccharide induces the association and coordinate activation of p53/56lyn and phosphatidylinositol 3-kinase in human monocytes. J Immunol 156(3):1157-1165. Ialenti A, Ianaro A, Moncada S, Di Rosa M. 1992. Modulation of acute inflammation by endogenous nitric oxide. Eur J Pharmacol 211(2):177-182. Jones SA. 2005. Directing transition from innate to acquired immunity: defining a role for IL-6. J Immunol 175(6):3463-3468. Kamimura D, Ishihara K, Hirano T. 2003. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1-38. Kasahara T, Matsushima K. 2001. Macrophage signaling, apoptosis, lectins and leukocyte trafficking. Trends Immunol 22(11):593-594. Kim JB, Han AR, Park EY, Kim JY, Cho W, Lee J, Seo EK, Lee KT. 2007. Inhibition of LPS-induced iNOS, COX-2 and cytokines expression by poncirin through the NF-kappaB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull 30(12):2345-2351. Lahti A, Jalonen U, Kankaanranta H, Moilanen E. 2003. c-Jun NH2-terminal kinase inhibitor anthra(1,9-cd)pyrazol-6(2H)-one reduces inducible nitric-oxide synthase expression by destabilizing mRNA in activated macrophages. Mol Pharmacol 64(2):308-315. Lakics V, Medvedev AE, Okada S, Vogel SN. 2000. Inhibition of LPS-induced cytokines by Bcl-xL in a murine macrophage cell line. J Immunol 165(5):2729-2737. Lee HJ, Hyun EA, Yoon WJ, Kim BH, Rhee MH, Kang HK, Cho JY, Yoo ES. 2006. In vitro anti-inflammatory and anti-oxidative effects of Cinnamomum camphora extracts. J Ethnopharmacol 103(2):208-216. Lien E, Ingalls RR. 2002. Toll-like receptors. Crit Care Med 30(1 Supp):S1-S11. Lopez-Bojorquez LN, Dehesa AZ, Reyes-Teran G. 2004. Molecular mechanisms involved in the pathogenesis of septic shock. Arch Med Res 35(6):465-479. Ma W, Lim W, Gee K, Aucoin S, Nandan D, Kozlowski M, Diaz-Mitoma F, Kumar A. 2001. The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem 276(17):13664-13674. Maeda S, Omata M. 2008. Inflammation and cancer: role of nuclear factor-kappaB activation. Cancer Sci 99(5):836-842. Medvedev AE, Kopydlowski KM, Vogel SN. 2000. Inhibition of lipopolysaccharide-induced signal transduction in endotoxin-tolerized mouse macrophages: dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene expression. J Immunol 164(11):5564-5574. Miyake K. 2004. Innate recognition of lipopolysaccharide by Toll-like receptor 4-MD-2. Trends Microbiol 12(4):186-192. Mogensen TH. 2009.Pathogen recognition and inflammatory signaling in innate immune defenses. Clin Microbiol Rev 22 , p240–273. Moncada S. 1999. Nitric oxide: discovery and impact on clinical medicine. J R Soc Med 92(4):164-169. Nakano H, Shindo M, Sakon S, Nishinaka S, Mihara M, Yagita H, Okumura K. 1998. Differential regulation of IkappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. Proc Natl Acad Sci U S A 95(7):3537-3542. Nathan C. 2002. Points of control in inflammation. Nature 420(6917):846-852. Nishimoto N, Kishimoto T. 2004. Inhibition of IL-6 for the treatment of inflammatory diseases. Curr Opin Pharmacol 4(4):386-391. Nussler AK, Billiar TR. 1993. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 54(2):171-178. Peter C. Taylor , Marc Feldmann. 2009.Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.Nature Reviews Rheumatology 5, 578-582 Pahl HL. 1999. Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18(49):6853-6866. Paul AT, Gohil VM, Bhutani KK. 2006. Modulating TNF-alpha signaling with natural products. Drug Discov Today 11(15-16):725-732. Robinson MJ, Cobb MH. 1997. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9(2):180-186. Ruslan Medzhitov.2008.Origin and physiological roles of inflammation. Nature 454, 428-435. Saklatvala J. 2007. Inflammatory signaling in cartilage: MAPK and NF-kappaB pathways in chondrocytes and the use of inhibitors for research into pathogenesis and therapy of osteoarthritis. Curr Drug Targets 8(2):305-313. Serhan CN, Brain SD, Buckley CD, Gilroy DW, Haslett C, O'Neill LA, Perretti M, Rossi AG, Wallace JL. 2007. Resolution of inflammation: state of the art, definitions and terms. FASEB J 21(2):325-332. Sweet MJ, Hume DA. 1996. Endotoxin signal transduction in macrophages. J Leukoc Biol 60(1):8-26. Vanden Berghe W, Plaisance S, Boone E, De Bosscher K, Schmitz ML, Fiers W, Haegeman G. 1998. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem 273(6):3285-3290. Wong ET, Tergaonkar V. 2009. Roles of NF-kappaB in health and disease: mechanisms and therapeutic potential. Clin Sci (Lond) 116(6):451-465. Yen YT, Liao F, Hsiao CH, Kao CL, Chen YC, Wu-Hsieh BA. 2006. Modeling the early events of severe acute respiratory syndrome coronavirus infection in vitro. J Virol 80(6):2684-2693. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/56071 | - |
dc.description.abstract | 發炎反應(Inflammation)為組織受傷或受微生物侵入時,體內所產生的自然防禦機制,一般具有紅、腫、熱、痛之典型特徵,引起微血管擴張、血流加速、血管通透性增加及白血球移行至發炎部位,進而吞噬病原體及受傷組織。在發炎反應的過程中,活化的免疫細胞還會分泌多種具有細胞毒殺作用(cytotoxic)或促發炎反應的細胞激素(proinflammatory cytokine)來促進並維持發炎反應的進行以助於個體清除外來的有害刺激;然而,在過度的發炎反應中,上述物質會大量產生而對個體產生傷害。近來研究指出,發炎反應和多種疾病狀態有關,例如:關節炎、阿茲海默症、多發性硬化症、氣喘、動脈硬化、自體免疫疾病、癌症甚至是急性的敗血症。因此尋找具有抗發炎活性的藥物來抑制過度的發炎反應便成為藥物開發的重要方向。
我們發現化合物5185的衍生物ctkf6f2具有抗發炎活性,並且在活性測試所使用的劑量下,不會影響細胞的存活率。實驗指出化合物ctkf6f2在10 μM時即可有效抑制受細菌內毒素(LPS)活化的鼠源巨噬細胞或人類的單核細胞所分泌的細胞激素,像是TNF-α及IL-6;和趨化素,像是MCP-1;也會抑制nitric oxide及自由基(ROS)的釋放。 敗血症為一常見的全身性發炎重症,其根本源自於免疫系統針對感染或創傷的過度反應,因此在活體實驗中,我們分別使用了內毒素(LPS)引發的內毒素血症及盲腸結紮穿刺手術(CLP)誘導敗血症此兩種動物模式來研究化合物ctkf6f2在活體發炎中的抗發炎活性。我們發現在此兩種模擬敗血症的發炎狀況中,化合物ctkf6f2都具有抑制發炎的現象,例如:有效降低敗血症小鼠血清中的發炎細胞激素含量(TNF-α與IL-6)與趨化素含量(MCP-1)、降低LPS和CLP誘發敗血症小鼠之死亡率、改善敗血症小鼠所受到的器官損傷。 在機制的探討方面,LPS活化巨噬細胞後所產生的下游訊息傳遞鏈以ROS產生、MAPK路徑及NF-κB路徑為主。在ROS生成路徑中,我們發現給予Ctkf6f2的情況下可以抑制NADPH oxidase 次單位p47及p67從細胞質移動到細胞膜的情形,而透過抑制NADPH oxidase的活化降低ROS的表現量;而在MAPK 路徑中,我們檢視了三種重要的激酶包括p38、ERK1/2、JNK的磷酸化現象,發現化合物ctkf6f2對於這三種激酶的磷酸化都有抑制作用;另外也檢視了NF-κB活化路徑中重要的因子:IκBα的磷酸化和降解(degradation)情形,發現化合物ctkf6f2也可抑制IκBα磷酸化和降解現象;此外,ctkf6f2也可從轉錄層級(transcriptional level)去抑制活化NF-κB路徑後所誘發的下游酵素,例如:iNOS及COX-2的表現。因此我們推測化合物ctkf6f2藉由抑制ROS產生和MAPK及NF-κB訊息傳遞路徑來抑制發炎反應。 | zh_TW |
dc.description.abstract | Inflammation, usually characterized by swelling, redness, pain, and heat, is a crucial function of the innate immune system for protecting the host against pathogens. Upon bacterial invasion, mammalian monocytes/ macrophages release a variety of inflammatory mediators such as pro-inflammatory and cytotoxic cytokines, chemokines and reactive oxygen/nitrogen species to defense harmful stimuli, but excessive inflammatory reaction leads to extensive tissue damage and manifestation of pathological states such as multiple sclerosis, asthma, arthritis, atherosclerosis, Alzheimer’s disease and cancer. Therefore, targeting on uncontrolled inflammation seems feasible to control numerous inflammation-associated diseases.
We discovered compound ctkf6f2 , a synthetic benzimidazole molecule , derivative of compound 5185, possesses anti-inflammatory effects in decreasing the release of pro-inflammatory cytokines including TNF-α and IL-6, chemokines including MCP-1 ,as well as decreased the production of nitric oxide and reactive oxygen species (ROS), and we also excluded its cytotoxicity by cell viability and LDH release assay. Furthermore, we found that ctkf6f2 attenuates some pathological syndromes of LPS-induced endotoxemia and CLP-induced sepsis in mice, such as decreasing the cytokine production, protecting the mice from tissue injury in septic conditions . These results suggest the beneficial effects of ctkf6f2 in septic animal models. In protein expression of LPS-stimulated macrophages, we observed that the molecular mechanism of ctkf6f2-mediated anti-inflammation is associated with decreasing phosphorylation of MAPK molecules such as ERK1/2, JNK and p38. Ctkf6f2 also inhibited phosphorylation of IκBα and reversed IκBα degradation and attenuated the expression of NF-κB-related downstream inducible enzymes like iNOS and COX-2. In addition, ctkf6f2 has been identified as an anti-inflammatory agent by inhibiting NADPH oxidase activity which leads to the reduction of reactive oxygen species (ROS) by inhibiting the membrane translocation of NADPH oxidase subunit p47phox and p67phox. Taken together, these results indicate that ctkf6f2 inhibits LPS-induced overactive inflammation by inhibiting NADPH oxidase-mediated ROS production and both the blockade of NF-κB and MAPK pathways. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T05:14:37Z (GMT). No. of bitstreams: 1 ntu-103-R00443002-1.pdf: 7265422 bytes, checksum: aa42c1dc1e1f4c63f4a44c1116abcd86 (MD5) Previous issue date: 2014 | en |
dc.description.tableofcontents | 中文摘要 i
Abstract iii Abbreviation Table v Chapter1 Introduction 1 1.1 Inflammation 1 1.2 Monocytes and macrophages 2 1.3 Macrophage-derived cytotoxic and proinflammatory mediators 4 1.3.1 Cytokines 4 1.3.1.1 Tumor Necrosis Factor-α (TNF-α) 5 1.3.1.2 Interleukin 6 (IL-6) 6 1.3.2 Chemokines 7 1.3.2.1 Monocyte chemoattractant protein-1 (MCP-1) 8 1.3.3 Nitric oxide (NO) 9 1.3.4 Reactive oxygen species 10 1.4 The signaling pathways of lipopolysaccharide (LPS) 11 1.4.1 The MAP kinase pathway 12 1.4.2 The NF-κB pathway 14 1.5 Sepsis 15 1.6 Cancer and inflammation 17 1.7 Aim of thesis 19 Chapter 2 Materials and Methods 30 2.1 Materials 30 2.2 Cell cultutre 31 2.2.1 Cell culture – RAW 264.7 macrophage cell 31 2.2.2 Cell culture – Murine peritoneal macrophage cell 31 2.2.3 Cell culture – Human THP-1 monocytic leukemia cell 32 2.3 Cell viability assay 32 2.4 LDH release assay 33 2.5 Nitric oxide assay 33 2.6 ROS measurement 34 2.7 Cytokine assays 35 2.8 Subcellular fractionation 36 2.9 Western blot analysis 36 2.10 In vivo assay (Animal model) 37 2.10.1 Animals 37 2.10.2 Animal Model of Endotoxemia: LPS-challenged endotoxemia 38 2.10.2.1 LPS challenge 38 2.10.3 Animal Model of Sepsis: CLP-induced sepsis 38 2.10.3.1 Cecal Ligation Puncture (CLP) 38 2.10.2.2 Mice whole blood and serum collection 39 2.10.2.3 Measurement of cytokine levels 39 2.10.2.4 Histological examination 39 2.11 Statistical analysis 40 Chapter 3 Results 41 3.1 Ctkf6f2 inhibits pro-inflammatory cytokines TNF-α and IL-6 production in LPS-stimulated phagocytes 41 3.2 Ctkf6f2 inhibits chemokine MCP-1 production in LPS-stimulated phagocytes 41 3.3 The effects of ctkf6f2 on cell cytotoxicity on murine macrophages in vitro and ex vivo 42 3.4 The effects of ctkf6f2 on cell integrity on murine macrophages in vitro and ex vivo 43 3.5 Ctkf6f2 inhibits nitric oxide production in LPS- stimulated RAW264.7 macrophages 43 3.6 Ctkf6f2 inhibits iNOS and COX-2 expression in LPS-stimulated RAW 264.7 cells 44 3.7 Ctkf6f2 inhibits ROS production in LPS-stimulated RAW 264.7 macrophages 45 3.8 Ctkf6f2 inhibits LPS-induced translocation of the cytosolic subunits p47phox and p67phox to the cellular membrane 46 3.9 Ctkf6f2 inhibits the phosphorylation of MAPK molecules in LPS- stimulated RAW 264.7 cells 47 3.10 Ctkf6f2 inhibits IκBα phosphorylation and degradation in LPS-induced RAW264.7 macrophages 47 3.11 The effects of ctkf6f2 on LPS-induced endotoxemia and CLP-induced sepsis model in vivo 48 3.11.1 Ctkf6f2 inhibits pro-inflammatory cytokines including TNF-α and IL-6 production and chemokines MCP-1 in vivo 49 3.11.2 Ctkf6f2 increases survival rate of mice with lethal administration of LPS and CLP surgery. 50 3.11.3 Effects of Ctkf6f2 on tissue injury in endotoxemia and sepsis models examined by histochemistry 50 Chapter 4 Discussion 75 Chapter 5 Conclusion and Perspectives 80 References 82 | |
dc.language.iso | en | |
dc.title | 化合物Ctkf6f2之抗發炎作用及機轉之探討 | zh_TW |
dc.title | The anti-inflammatory effect and
mechanism of action of compound Ctkf6f2 | en |
dc.type | Thesis | |
dc.date.schoolyear | 102-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄧哲明(Che-Ming Teng),顏茂雄(Mao-Hsiung Yen),楊春茂(Chuen-Mao Yang),吳文彬(Wen-Bin Wu) | |
dc.subject.keyword | 脂多醣,發炎反應,敗血症, | zh_TW |
dc.subject.keyword | Lipopolysaccharide,Inflammation,sepsis, | en |
dc.relation.page | 90 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2014-08-18 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-103-1.pdf 目前未授權公開取用 | 7.1 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。